Risk factors and management of lung cancer in idiopathic pulmonary fibrosis: A comprehensive review

Gamze Kirkil; Nesrin Mogulkoc; Dragana Jovanovic

doi:10.36141/svdld.v42i1.15604

Authors

Gamze Kirkil Department of Chest Disease, University of Firat, Elazig, Türkiye
Nesrin Mogulkoc Department of Chest Disease, University of Ege, İzmir, Türkiye
Dragana Jovanovic Department of Internal Medicine, University of Belgrade, Serbia

Keywords:

idiopathic pulmonary fibrosis, lung cancer risk, fibrosis-associated lung cancer, management strategies, pulmonary fibrosis and cancer

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease. Lung cancer (LC) is among the most crucial comorbidity factors in patients with IPF. IPF patients that are diagnosed with LC have a reduced mean survival time. Therapeutic strategies for LC in patients with IPF need to be adapted according to the individual treatment risk. Life-threatening acute exacerbation (AE) of IPF may occur in association with cancer treatment, thereby severely restricting the therapeutic options for IPF-associated LC. Because LC and anticancer treatments can worsen the prognosis of IPF, the prevention of LC is as critical as managing patients with IPF.

References

Kato E, Takayanagi N, Takaku Y, et al. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2018; 4: 00111-2016.

Turner-Warwick M, Lebowits M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35; 496–9.

Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. Population-based cohort study. Am J Respir Crit Care Med 2000; 161: 5– 8.

Karampitsakos T, Spagnolo P, Mogulkoc N, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe. Respirology 2023; 28: 56–65.

Song MJ, Kim SY, Park MS, Kang MJ, Lee SH, Park SC. A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis. Scientific Reports 2021; 11: 2596

Whittaker Brown SA, Dobelle M, Padilla M, et al. Idiopathic pulmonary fibrosis and lung cancer: A systematic review and meta-analysis. Ann Am Thorac Soc 2019; 16: 1041-51.

Miura Y, Saito T, Tanaka T, et al. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Invest 2018; 56: 72-9.

Yoo H, Jeong BH, Chung MJ, Lee KS, Kwon OJ, Chung MP. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: A retrospective cohort study. BMC Pulm Med 2019; 19: 149.

Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015; 147: 157–64.

Zhu M, Yi J, Su Y, et al. Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis. Thorac Cancer 2023; 14(19): 1874-82.

Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84: 52-9.

Carpagnano GE, Lacedonia D, Soccio P, Caccavo I, Patricelli G, Foschino Barbaro MP. How strong is the association between IPF and lung cancer? An answer from airway’s DNA. Med Oncol 2016; 33: 119.

Kawasaki H, Ogura T, Yokose T, Nagai K, Nishiwaki Y, Esumi H. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Hum Pathol 2001; 32: 1043-9.

Demopoulos K, Arvanitis DA, Vassilakis DA, Siafakas NM, Spandidos DA. MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med. 2002; 6(2): 215-22.

Guyard A, Danel C, Theou-Anton N, et al. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibrosis. Respir Res 2017; 18(1): 120.

Hwang JA, Kim D, Chun SM, et al. Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis. J Pathol 2018; 244: 25-35.

Antoniou KM, Samara KD, Lasithiotaki I GA, et al. Differential telomerase expression in idiopathic pulmonary fibrosis and nonsmall cell lung cancer. Oncol Rep 2013; 30: 2617-224.

Selman M, Pardo A. Stochastic age-related epigenetic drift in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014; 190(12): 1328-30.

Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One 2012; 7(4): e33770.

Yang IV, Pedersen BS, Rabinovich E, et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190(11): 1263-72.

Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207(8): 1589-97.

Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 2013; 49(3): 604-15.

Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Experimental & Molecular Medicine 2023; 55: 1322–32.

Samarelli AV, Masciale V, Aramini B, et al. Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. Int J Mol Sci 2021; 22: 12179.

Buechler MB, Pradhan RN, Krishnamurty AT, et al. Cross-tissue organization of the fibroblast lineage. Nature 2021; 593: 575–9.

Pechkovsky DV, Prele CM, Wong J, et al. STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF. Am J Pathol 2012; 180: 1398–412.

Larsson O, Diebold D, Fan D, et al. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS One 2008;3:e3220.

Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35(3): 496-504.

Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 2013; 22: 265-72.

Epstein Shochet G, Brook E, Israeli-Shani L, Edelstein E. Shitrit D fibroblast paracrine TNF-alpha signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF). Respir Res 2017; 18: 122.

Epstein Shochet G, Brook E, Eyal O, Edelstein E, Shitrit D. Epidermal growth factor receptor (EGFR) paracrine upregulation in idiopathic pulmonary fibrosis (IPF) fibroblasts is blocked by nintedanib. Am J Physiol Lung Cell Mol Physiol 2019; 316(6): 1025-34.

Wipff P J, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGF-Beta1 from the extracellular matrix. J Cell Biol 2007; 179 (6): 1311–23.

Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One 2010; 5: e9224.

Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 2014; 40: 40–50.

O'Reilly S, Ciechomska M, Cant R, van Laar JM. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via gremlin protein. J Biol Chem 2014; 289: 9952–60.

Wang JH, Zhao L, Pan X, et al. Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-beta1 signaling pathway. Lab Investig 2016; 96: 1035.

Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 2006; 3: 413–7.

Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007; 35: 661–4.

Hinz B. Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. Proc Am Thorac Soc 2012; 9: 137–47.

Huang Y, Xie Y, Abel PW, et al. TGF-β1- induced miR-424 promotes pulmonary myofibroblast differentiation by targeting slit2 protein expression. Biochem Pharmacol 2020; 180: 114172.

Tsukui T, Sun KH, Wetter J.B, et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun 2020; 11 (1): 1920.

Barrett RL, Pure E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. eLife 2020; 9: e57243.

Wong KY, Cheung AH, Chen B, et al. Cancer-associated fibroblasts in nonsmall cell lung cancer: From molecular mechanisms to clinical implications. Int J Cancer. 2022; 151: 1195–215.

Ershaid N, Sharon Y, Doron H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast Cancer progression and metastasis. Nature Communications 2019; 10: 4375.

Avery D, Govindaraju P, Jacob M, Todd L, Monslow J, Pure´ E. Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. Matrix Biology 2018; 67: 90–106.

Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.

Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3: 349-63.

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016; 16: 582-98.

Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med 2014; 211: 1503-23.

Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 2016; 30: 836-48.

Maacha S, Bhat AA, Jimenez L, et al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol Cancer 2019; 18: 1-16.

Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012; 151: 1542-56.

Webber JP, Spary LK, Sanders AJ, et al. Differentiation of tumour promoting stromal myofibroblasts by cancer exosomes. Oncogene 2015; 34: 290-302.

Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene 2017; 36: 1770-8.

Giusti I, Di Francesco M, D'Ascenzo S, et al. Ovarian cancer-derived extracellular vesicles affect normal human fibroblast behavior. Cancer Biol Ther 2018; 19: 722-34.

Kai F, Drain AP, Weaver VM. The extracellular matrix modulates the metastatic journey. Developmental Cell 2019; 49: 332–46.

Ohlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 2017; 214: 579–96.

Bhattacharjee S, Hamberger F, Ravichandra A, et al. Tumor restriction by type I collagen opposes tumor promoting effects of cancer-associated fibroblasts. J Clin Invest 2021; 131:146987.

Zhang X, Zheng S, Hu C, et al. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene 2022; 41: 2372–89.

Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov 2019; 9: 1102–23.

Kerdidani D, Aerakis E, Verrou KM, et al. Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. J Exp Med 2022; 219: e20210815.

Yamauchi M, Gibbons DL, Zong C, Fradette JJ, Bota-Rabassedas N, Kurie JM. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in Cancer. Matrix Biology 2020: 91-92: 8–18.

Bartoschek M, Oskolkov N, Bocci M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun 2018; 9: 5150.

Krishnamurty AT, Shyer JA, Thai M, et al. LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 2022; 611: 148–54.

Su S, Chen J, Yao H, et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 2018; 172; 841–56.

Marchioni A, Tonelli R, Rossi G, et al. Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball”. Ann Intensive Care 2020; 10: 13.

Tschumperlin DJ, Dai G, Maly IV, et al. Mechanotransduction through growth-factor shedding into the extracellular space. Nature 2004; 429: 83–6.

Yamato H, Kimura K, Fukui E, et al. Periostin secreted by activated fibroblasts in idiopathic pulmonary fibrosis promotes tumorigenesis of non-small cell lung cancer. Sci Rep 2021; 11: 21114.

Yang J, Pan X, Wang L, Yu G. Alveolar cells under mechanical stressed niche: critical contributors to pulmonary fibrosis. Mol Med 2020; 26: 95.

Alvarado-Estrada K, Marenco-Hillembrand L, Maharjan S, et al. Circulatory shear stress induces molecular changes and side population enrichment in primary tumor-derived lung cancer cells with higher metastatic potential. Sci Rep 2021; 11: 2800.

Choe C, Shin YS, Kim C, et al. Crosstalk with cancer associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. Onco Targets Ther 2015; 8: 3665-78.

Conte E, Gili E, Fruciano M, et al. PI3K p110g overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: In vitro effects of its inhibition. Lab Invest 2013; 93: 566-76.

Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D. Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest 2019; 156: 383-91.

Caraci F, Gili E, Calafiore M, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res 2008; 57: 274-82.

Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett 2005; 222: 1-10.

Otsuki Y, Saya H, Arima Y. Prospects for new lung cancer treatments that target EMT signaling. Dev Dyn 2018; 247(3): 462-72.

Chilosi M, Poletti V, Zamò A, et al. Aberrant Wnt/β-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162: 1495–502.

Tzouvelekis A, Antoniou K, Kreuter M, et al. The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrO-SIS) survey. International survey and call for consensus. ERJ Open Res 2021; 7: 00529–2020.

Tzouvelekis A, Spagnolo P, Bonella F, et al. Patients with IPF and lung cancer: Diagnosis and management. Lancet Respir Med 2018; 6: 86-8.

Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014; 190: 773–9.

Taya T, Chiba H, Yamada G, et al. Risk factors for acute exacerbation of idiopathic interstitial pneumonia in patients undergoing lung cancer treatment. Japan J Clin Oncol 2019; 49: 1126–33.

Kewalramani N, Machahua C, Poletti V, Cadranel J, Wells AU, Funke-Chambour M. Lung cancer in patients with fibrosing interstitial lung diseases: An overview of current knowledge and challenges. ERJ Open Res 2022; 8: 00115-2022.

Tane S, Ando Y, Matsumoto G, Ueda S, Uchino K. Basal segment deep wedge resection for lung cancer with pulmonary fibrosis. Gen Thorac Cardiovasc Surg 2022; 70: 413–5.

Im Y, Chung MP, Lee KS, et al. Impact of interstitial lung abnormalities on postoperative pulmonary complications and survival of lung cancer. Thorax 2023; 78: 183–90.

Chen H, Senan S, Nossent EJ, et al. Treatment related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: A systematic review. Int J Radiat Oncol 2017; 98: 622–31.

Sato T, Watanabe A, Kondo H, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg 2015; 149: 64-9.

Mizuno Y, Iwata H, Shirahashi K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg 2012; 41: 161–5.

Yamauchi Y, Izumi Y, Inoue M, et al. Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. PLoS One 2011; 6: 29053.

Ito H, Nakayama H, Yokose T, Yamada K. Prophylaxis for acute exacerbation of interstitial pneumonia after lung resection. Asian Cardiovasc Thorac Ann 2014; 8. 948–54.

Iwata T, Yoshino I, Yoshida S, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Respir Res 2016; 17: 90.

Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced nonsmall cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 2011; 71: 70 –4.

Ma W, Li H, Tian Z, Wang S, Zheng X, Hou J. Complete regression of pulmonary squamous carcinoma in IPF following gemcitabine plus cisplatin: A case report and literature review. BMC Pulm Med 2020; 20: 69.

Watanabe N, Niho S, Kirita K, et al. Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 2015; 76: 69-74.

Minegishi Y, Gemma A, Homma S, et al. Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: Nationwide surveillance in Japan. ERJ Open Res 2020; 6: 00184-2019.

Sakurada T, Kakiuchi S, Tajima S, et al. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 2015; 49: 398-404.

Kenmotsu H, Naito T, Kimura M, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 2011; 6: 1242-6.

Su Q, Zhu EC, Wu JB, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: A systematic review and meta-analysis. Front Immunol 2019; 10: 108.

Chen YJ, Chen LX, Han MX, Zhang TS, Zhou ZR, Zhong DS. The efficacy and safety of chemotherapy in patients with nonsmall cell lung cancer and interstitial lung disease: A PRISMA-compliant bayesian meta-analysis and systematic review. Medicine (Baltimore) 2015; 94: 1451.

Kinoshita T, Azuma K, Sasada T, et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett 2012; 4: 477-82.

Kanaji N, Shimizu J, Sakai K, et al. Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. Ther Adv Respir Dis 2020; 14: 1–12.

Yamamoto Y, Yano Y, Kuge T, et al. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. Thorac Cancer 2020; 11: 3317–25.

Landi C, Carleo A, Vantaggiato L, et al. Common molecular pathways targeted by nintedanib in cancer and IPF: A bioinformatic study. Pulm Pharmacol Ther 2020; 64: 101941.

Okamoto I, Miyazaki M, Takeda M, et al. Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: A phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. J Thorac Oncol 2015; 10: 346-52.

Daga H, Takeda K, Okada H, et al. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced nonsmall cell lung cancer. Cancer Chemother Pharmacol 2015; 76: 1225-33.

Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-55.

Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer 2016; 102. 65-73.

Otsubo K, Kishimoto J, Ando M, et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: A randomised phase 3 trial. Eur Respir J 2022; 60: 2200380.

Kai Y, Matsuda M, Fukuoka A, et al. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis. Thorac Cancer 2021; 12: 1457–60.

Shiratori T, Tanaka H, Tabe C, et al. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review. Thorac Cancer 2020; 11: 1720–3.

Qin W, Zou J, Huang Y, et al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. Oncoimmunology 2020; 9: 1824631.

Gavert N, Ben-Ze’ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008; 14: 199–209.

Fujiwara A, Shintani Y, Funaki S, et al. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Lung Cancer 2017; 106: 8–16.

Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer 2016; 16: 176.

Bauer Y, Tedrow J, de Bernard S, et al. A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2015; 52: 217–31.

de Ruysscher D, Faivre-Finn C, Moeller D, et al. Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC). European Organization for Research and Treatment of Cancer (EORTC) Recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol 2017; 124: 1–10.

Kim HC, Lee S, Song JW. Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients. Sci Rep 2021; 11: 8312.

Okubo M, Itonaga T, Saito T, et al. Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours. Br J Radiol 2017; 90: 20160508.

Onishi H, Yamashita H, Shioyama Y, et al. Stereotactic body radiation therapy for patients with pulmonary interstitial change: high incidence of fatal radiation pneumonitis in a retrospective multi-institutional study. Cancers 2018; 10: 257.

Castillo R, Pham N, Ansari S, et al. Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. Radiat Oncol 2014; 9: 74.

Kim H, Pyo H, Noh JM, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: Comparison between X-ray and proton therapy. Radiat Oncol 2019; 14: 19.

Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: A single center experience. Radiat Oncol 2016; 11: 56.

Kwan SW, Mortell KE, Talenfeld AD, Brunner MC. Thermal ablation matches sublobar resection outcomes in older patients with early-stage non–small cell lung cancer. J Vasc Interv Radiol 2014; 25: 1–9.

Kashima M, Yamakado K, Takaki H, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: A single center’s experiences. Am J Roentgenol 2011; 197: 576–80.

Jiang B, Mcclure MA, Chen T, Chen S. Efficacy and safety of thermal ablation of lung malignancies: A network meta-analysis. Ann Thorac Med 2018; 13: 243–50.

Qin W, Liu B, Yi M, et al. Antifibrotic agent pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model. Radiat Res 2018; 190: 396-403.

Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 2018; 362: k3529.

Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017; 35: 709–17.

Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 2016; 22: 6051–60.

Teng F, Li M, Yu J. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. BMC Med 2020; 18: 275.

Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017; 50(2): 1700050.

Kato T, Masuda N, Nakanishi Y, et al. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer 2017; 104: 111-8.

Suresh K, Voong KR, Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. Thorac Oncol 2018; 13(12): 1930e9.

Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera MP. Immune checkpoint inhibitor-related pneumonitis in lung cancer: Real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 2021; 160 (2): 731−42.

Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Canc 2004; 91(Suppl 2): S3e10.

Shibaki R, Murakami S, Matsumoto Y, et al. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother 2020; 69: 15–22.

Yamaguchi T, Shimizu J, Hasegawa T, et al. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer 2018; 125: 212–7.

Dobre IA, Frank AJ, D'Silva KM, Christiani DC, Okin D, Sharma A, Montesi SB. Outcomes of patients with interstitial lung disease receiving programmed cell death 1 inhibitors. A retrospective case series. Clin Lung Cancer 2021; 22(5): 738-44.

Ikeda S, Kato T, Kenmotsu H, et al. A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis. J Thorac Oncol 2020; 15(12): 1935–42.

Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: A systematic review and meta-analysis. Chest 2022; 161 (6): 1675−86.

Tasaka Y, Honda T, Nishiyama N, et al. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 2021; 155: 120-6.

Fujimoto D, Yomota M, Sekine A, et al. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm phase II trial. Lung Cancer 2019; 134: 274–8.

Tan X, Tang X, Jiang Y. Immunotherapy for combined pulmonary fibrosis and emphysema with advanced lung cancer: two case reports and a concise review. Transl Cancer Res 2022; 11(11): 4194-9.

Khunger M, Velcheti V. A case of a patient with IPF with lung squamous cell carcinoma treated with nivolumab. J Thorac Oncol 2017; 12(7): 96-7.

Duchemann B, Pluvy J, Crestani B, Zalcman G, Nunes H. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. Eur J Cancer 2021; 145: 179e82.

Celada LJ, Kropski JA, Herazo-Maya JD, et al. PD-1 up-regulation on CD4 (+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production. Sci Transl Med 2018; 10: eaar8356.

Jovanovic D, Milenkovic MR, Kotur Stevuljevic J, Markovic J, Ceriman V, Kontic M, Trifuvonic VS. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis—a pilot study. J Thorac Dis 2018; 10(12): 6660–9.

Habiel DM, Espindola MS, Kitson C, Azzara AV, Coelho AL, Stripp B, Hogaboam CM. Characterization of CD28null T cells in idiopathic pulmonary fibrosis. Mucosal Immunol 2019; 12(1): 212-22.

Ni K, Liu M, Zheng J, et al. PD-1/PD-L1 pathway mediates the alleviation of pulmonary ﬁbrosis by human mesenchymal stem cells in humanized mice. Am J Respir Cell Mol Biol 2018; 58(6): 684–95.

Geng Y, Liu X, Liang J, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight 2019; 4(6): e125326.

Qin W, Zou J, Huang Y, et al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. Oncoimmunology 2020; 9(1): 1824631.

Yamakawa H, Oba T, Ohta H, et al. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report. BMC Pulm Med 201919(1)156.

Naoi H, Suzuki Y, Mori K, et al. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis. Thorax 2022; 77: 727–30.